Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 73

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 73
---
 objectives, non -equitycompensation, and equity grants for the Chief Executive Officer; •recommending to the board of directors non -equitycompensation and equity grants for the directors; •reviewing and discussing with the board of directors corporate succession plans for the Chief Executive Officer and key officers; •reviewing and discussing with management its talent development and related initiatives; •assisting the board of directors with its oversight of our strategies, programs, and initiatives related to employee health, safety, and well -being, engagement, pay equity, and diversity and inclusion; •selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the Compensation Committee’s compensation advisors; •reviewing and recommending to the board of directors employment agreements, severance arrangements and change -of -controlagreements or provisions for executive officers and other senior management, as appropriate; and •reviewing the policies relating to compensation and benefits of employees. Nominating and Corporate Governance Committee The members of our nominating and corporate governance committee are Dr. Rolfe, Ms. LaPorte and Mr. Byrnes. Dr. Rolfe serves as the chairperson of the committee. Our board of directors has determined that each of Dr. Rolfe, Ms. LaPorte and Mr. Byrnes is independent under the applicable Nasdaq listing standards. 40 The nominating and corporate governance committee’s main function is to consider candidates for board membership and oversee our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The nominating and corporate governance committee’s responsibilities include, among other things: •recommending to the board of directors for its approval criteria for board of directors and committee membership; •establishing a process for identifying and evaluating board of director candidates, including nominees recommended by stockholders; •identifying individuals qualified to become members of the board of directors; •recommending to the board of directors the persons to be nominated for election as directors and to each of the committees of the board of directors; •developing and recommending to the board of directors corporate governance guidelines and periodically reviewing those guidelines and the code of conduct and business ethics and recommending any changes; and •overseeing a periodic evaluation of the board of directors and its committees. Board and Committee Meetings Attendance During the fiscal year ended December 31, 2024, our board of directors met 16 times, our Audit Committee met four times, and our Compensation Committee met six